Media

ReNewVax are pleased to announce the appointment of Simon Thorn as Chief Financial Officer. An accomplished senior executive with significant expertise in the venture capital sector working hands-on with SME’s to help them to scale, prior to joining ReNewVax, Simon...

ReNewVax has been included in the “Northern Life Sciences” supplement published by City AM.  The supplement shines a spotlight on the achievements of the sector in the North, with features on this year’s Bionow Award winners and the important role that Bionow...

We were delighted to receive the award for Start-up of the year at last night’s Annual Bionow Awards Dinner. Commenting on the award, Neil Murray, ReNewVax’s CEO, said, “It’s a great honour to receive the Bionow Start-up of the Year Award.  This is testament to the...

ReNewVax are pleased to announce the appointment of Dr Miguel Leon-Rios as Head of Research. An experienced immunologist, Miguel has been intimately involved in the translational development of our lead program RVX-001, both during his time at the University of...

ReNewVax are pleased to announce the appointment of Dr Simon Cruwys and Dr. Carolyn Horrocks to the Board of the Company. With over 30 years experience in academic and industrial research, Simon has been involved with ReNewVax since its inception. As Head of the...

ReNewVax is proud to participate in BioInfect 2024, a major conference set to commemorate the ten-year anniversary of the influential O’Neill Review on AMR. Hosted at The Spine in Liverpool’s Knowledge Quarter, the event will bring together key figures from academia...

ReNewVax has been featured in this autumn’s edition of Drug Target Review, sharing insights into our quest for a universal pneumococcal vaccine. ‘Why innovation is the key to unlocking a universal pneumococcal vaccine’, details how the principle of reverse vaccinology...

ReNewVax has been named ‘One to Watch’ in UKTN’s 2023 guide to University Spinouts. University spinouts are companies founded to commercialise innovative technologies, products or services that have originated from academic research conducted within universities....

This month, European Pharmaceutical Review features a piece from ReNewVax’s Chief Executive Dr. Neil Murray for its Formulation issue.  In the piece, Neil explores the importance of new bacterial vaccines in the context of antimicrobial resistance and examines...

This month, North West Business Insider has named ReNewVax as one of thirty businesses across the region carrying out exciting work in their sectors.  The Most Exciting Companies list features a range of companies shaking up their sectors, whether it be...

ReNewVax appears on The Northern Agenda podcast ReNewVax was invited to appear on The Northern Agenda’s second birthday podcast!  The episode saw hosts Rob Parsons and Dan McLaughlin discuss the last two years in Northern politics and ask whether the North is...

ReNewVax showcased in the latest edition of Laboratory News ReNewVax is featured in the April/May edition of Laboratory News with an article highlighting our RVX-001 pneumococcal vaccine program. In the article, we explore how we are deploying our novel platform...